...
首页> 外文期刊>Applied immunohistochemistry and molecular morphology: AIMM >Adrenocortical carcinoma: A comprehensive immunohistochemical study of 40 cases
【24h】

Adrenocortical carcinoma: A comprehensive immunohistochemical study of 40 cases

机译:肾上腺皮质癌:40例免疫组织化学综合研究

获取原文
获取原文并翻译 | 示例
           

摘要

Adrenocortical carcinomas (ACC) are uncommon tumors of the adrenal cortex that are known to follow an aggressive clinical course. The distinction of these tumors from other neoplasms may sometimes prove difficult due to overlapping clinical, morphologic, and even immunophenotypical features. To this end, we performed a comprehensive immunohistochemical analysis using traditional and novel markers in 40 cases of ACC. An immunohistochemical panel consisting of 10 traditional and novel antibodies was applied to whole tissue sections of ACC including high-molecular weight cytokeratin (HMWCK), low-molecular weight cytokeratin (CAM5.2), inhibin-α, melan A, chromogranin A, synaptophysin, calretinin, steroid receptor coactivator-1 (SRC-1), Pax8, and Ki67. The percentage of positive tumor cells as well as the intensity of staining were evaluated and scored; for Ki67 the percentage of positive tumor cells was recorded. Positive staining was observed for SRC-1 (39/40; 97.5%), inhibin-α (37/40; 92.5%), calretinin (32/40; 80%), synaptophysin (29/40; 72.5%), melan A (26/40; 65%), and CAM5.2 (9/40; 22.5%). Rare cases showed positivity for chromogranin A (2/40; 5%) and Pax8 (1/40; 2.5%). None of the cases showed any reactivity with HMWCK. The Ki67 index ranged from <5% to 20%. We conclude that there is no single specific marker to reliably distinguish ACC from other primary or metastatic neoplasms. However, a combination of immunohistochemical stains in a panel consisting of SRC-1, inhibin-α, calretinin, and HMWCK may be of aid in the differential diagnosis of these tumors. In addition, Pax8 is only rarely positive in ACC, which is a useful tool in their separation from renal neoplasms.
机译:肾上腺皮质癌(ACC)是肾上腺皮质的罕见肿瘤,已知会遵循积极的临床过程。由于重叠的临床,形态甚至免疫表型特征,有时可能难以区分这些肿瘤与其他肿瘤。为此,我们在40例ACC中使用传统和新型标记物进行了全面的免疫组化分析。将由10种传统和新型抗体组成的免疫组化面板应用于ACC的整个组织切片,包括高分子量细胞角蛋白(HMWCK),低分子量细胞角蛋白(CAM5.2),抑制素-α,黑色素A,嗜铬粒蛋白A,突触素,钙调蛋白,类固醇受体共激活因子1(SRC-1),Pax8和Ki67。评估并评分阳性肿瘤细胞的百分比以及染色强度。对于Ki67,记录阳性肿瘤细胞的百分比。观察到SRC-1(39/40; 97.5%),抑制素-α(37/40; 92.5%),降钙素(32/40; 80%),突触素(29/40; 72.5%),黑色素阳性染色A(26/40; 65%)和CAM5.2(9/40; 22.5%)。罕见病例显示嗜铬粒蛋白A(2/40; 5%)和Pax8(1/40; 2.5%)呈阳性。没有一个病例显示与HMWCK有任何反应。 Ki67指数的范围从<5%到20%。我们得出结论,没有单一的特异性标志物可以可靠地将ACC与其他原发性或转移性肿瘤区分开。但是,由SRC-1,抑制素-α,钙调蛋白和HMWCK组成的组中的免疫组化染色组合可能有助于这些肿瘤的鉴别诊断。此外,Pax8在ACC中很少是阳性的,这是从肾脏肿瘤中分离出来的有用工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号